Cost variation among anxiolytic drugs

Ajay Kumar Shukla, Neelesh Arya


Background: Indian pharmaceuticals market stands third and thirteenth largest in terms of value and volume in the Global Pharmaceutical Industry respectively. Anxiety disorders are one of the most common mental illnesses affecting more than 15% of the population at some point in their life span. Treatment of anxiety disorders usually follows a long term treatment. Cost of the treatment is an important factor determining the adherence to the treatment.

Methods: Data relevant to various brands of anxiolytic drug available in the Indian market particular drug obtained from “Current Index of Medical Specialties” (CIMS) October 2017 - January 2018 was used to calculate the cost ratio and percentage cost variation.

Results: There are 16 anxiolytic drugs in the form of 44 different formulations and 384 brands available in the Indian market. Among anxiolytic drugs, highest cost ratio and percent cost variation is for diazepam 5mg, followed by alprazolam 1mg and hydroxyzine 10mg. Highest number of brands of anxiolytic drugs available in Indian market are for clonazepam 0.5mg followed by alprazolam 0.5mg and escitalopram 10mg.

Conclusions: In Indian market, there is availability of large number of brands with wide and variable cost variations among the various brands of the anxiolytic drugs.


Anxiety disorders, Compliance, Cost variation, Health economics

Full Text:



Indian Pharmaceutical Industry. Available at: Accessed 10th February 2018.

Of India’s healthcare spend, 2/3 out of patients’ pockets: Study. Available at: Accessed 10th February 2018.

Morbidity, Health Care and the Condition of the Aged NSS 60th round (January – June 2004) National Sample Survey Organisation Ministry of Statistics and Programme Implementation Government of India 2006. Available at: Accessed 10th February 2018.

Shukla AK, Agnihotri A. Cost analysis of antipsychotic drugs available in India. Int J Basic Clin Pharmacol. 2017;6:669-74.

Shukla AK, Sharma P. Cost variation study of antidepressant drugs. Int J Basic Clin Pharmacol. 2016;5:1816-21.

Shukla AK, Mehani R. Cost analysis of antiepileptic drugs available in India. Int J Basic Clin Pharmacol. 2016;5:1636-40.

Shukla AK, Sharma P. Cost variation analysis of antidyslipidemic drugs. Int J Basic Clin Pharmacol. 2016;5:1850-5.

Atack JR. Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. Curr Drug Targets CNS Neurol Disord. 2003;2:213-32.

O’Donnell JM, Bies RR, Shelton RC. Drug Therapy of Depression and Anxiety Disorders. In: Brunton LB, Hilal-DanDan R, Knollman BC, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 13th Ed. New York, NY: McGraw-Hill; 2018:267-277.

Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Archives of internal medicine. 2006 Feb 13;166(3):332-7.

Akila L, Rani RJ. Cost analysis of different brands of antianginal drugs available in India. Int J Basic Clin Pharmacol. 2015;4:860-3.

National List of Essential Medicines 2015. Available at:,%202015.pdf. Accessed 10th February 2018.

The drugs (prices control) order, 2013. Available at: Accessed 10th February 2018.

Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: A systematic review. PLoS Med 2007;4:e283.

Ho PM, Bryson CL, Rumsfeld JS. Medication Adherence: Its Importance in Cardiovascular Outcomes. Circulation. 2009;119:3028-35.

Frazier LM, Brown JT, Divine GW, Fleming GR, Philips NM, Siegal WC, et al. Can physician education lower the cost of prescription drugs? A prospective, controlled trial. Ann Intern Med. 1991;115:116-21.

Medical council of India 2016. Available at: Accessed 10th February 2018.

Singal GL, Nanda A, Kotwani A. A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Indian J Pharmacol. 2011;43:131-6.